RESEARCH TRIANGLE PARK, N.C.,
May 2, 2011 /PRNewswire/ -- Grifols,
S.A. (GRF.MC) and Talecris Biotherapeutics Holdings Corp. (NASDAQ:
TLCR) announced today they have signed a Consent Agreement with the
staff of the Bureau of Competition of the U.S. Federal Trade
Commission (FTC) that outlines the conditions necessary for
Grifols' acquisition of Talecris to proceed. The Consent
Agreement remains subject to approval by the FTC Commissioners
before the transaction can be completed.
To satisfy the Consent Agreement conditions, Grifols has signed
documents agreeing to the sale of select assets and has entered
into certain commercial, lease and manufacturing agreements with
the Italian company Kedrion for up to seven years. These
agreements refer to four main areas:
- Kedrion and Grifols enter into a contract manufacturing
agreement to fractionate and purify Kedrion's plasma; and to
deliver IVIG and Albumin under Kedrion's private label, and Factor
VIII under the trade name Koate, all of them for sale only in the
U.S.
- Grifols sells to Kedrion the Melville, N.Y. fractionation facility. Grifols
will manage the facility for up to a four-year period under a lease
agreement with Kedrion
- Grifols sells to Kedrion Talecris' U.S. FVIII business
(Koate)
- Grifols sells to Kedrion two Talecris plasma collection
centers
According to Grifols, neither the Consent Agreement nor the
agreements signed with Kedrion will affect the operating synergies
that Grifols expects to achieve through the acquisition of
Talecris. Until the conclusion of the acquisition is formally
announced, both companies remain independent and will conduct
business as usual.
About Grifols
Grifols is a Spanish holding company, specializing in the
hospital-pharmaceutical sector, and with a presence in over 90
countries. Since May 2006 it has been
listed on the Spanish Continuous Market, and it is included in the
Ibex-35. Grifols is the leading European plasma products company,
and the fourth-largest producer in the world. The company plans to
strengthen its position within the industry as a vertically
integrated company, on the basis of its ongoing investment program.
In terms of raw material, Grifols has secure plasma supplies from
its network of 80 plasmapheresis centers in the United States, while its production plants
in Barcelona (Spain) and Los
Angeles (United States)
ensure that it has the fractionation capacity to satisfy rising
demand. In addition, the company has implemented an ambitious
investment plan to enable it to deliver sustained growth over the
next 8 to 10 years.
About Talecris Biotherapeutics: Inspiration.
Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and
biotechnology company that discovers, develops and produces
critical care treatments for people with life-threatening disorders
in a variety of therapeutic areas including immunology,
pulmonology, neurology and hemostasis. For more information, please
visit: http://www.talecris.com/
SOURCE Talecris Biotherapeutics